Search Results
Your search for ,kEY matches 7151 pages
Showing 3451 - 3500Lifileucel After Disease Progression in Metastatic Melanoma: Durable Responses Achieved in Phase II Trial
Despite the fact that we have made significant progress in metastatic melanoma with immune checkpoint inhibitors—now the standard of care—most patients experience disease progression and are left without approved treatments. There is a need for newer treatments with clinical benefit. Lifileucel, an ...
Targeting LAG-3 and PD-1 With Relatlimab and Nivolumab: A New Option Under Study in Advanced Melanoma
Immune checkpoint inhibition has been established as an effective treatment for patients with metastatic melanoma. A novel immunotherapeutic combination—this one targeting the LAG-3 (lymphocyte-activation gene 3) and PD-1 immune checkpoints—delayed the time to disease progression significantly more ...
KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
Novel Monoclonal Antibody Emerges as Potential First-Line Standard in Nasopharyngeal Cancer
A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial presented at the 2021 ASCO Annual Meeting by investigators from China.1 In the study, toripalimab, an anti–PD-1 monoclonal antibody, ...
EMPOWER-Lung 1: Cemiplimab-rwlc Improves Outcomes in First-Line Treatment of NSCLC With Brain Metastases
First-line treatment with cemiplimab-rwlc monotherapy improved overall survival, progression-free survival, and objective response rates compared with chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50% and clinically stable treated brain...
Expert Point of View: Nicolas Girard, MD, PhD
Invited discussant Nicolas Girard, MD, PhD, of the Curie Institute, Paris, said: “A major challenge in non–small cell lung cancer is what happens when osimertinib resistance develops.” “A key takeaway point from this study is that the efficacy is driven by resistance mechanism. The overall...
Survey Examines Oncology Clinician Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer
Less than half of community oncologists surveyed indicated that they use biomarker testing to guide patient discussions compared with 73% of academic clinicians, according to a report by Boehmer et al presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World...
Inclusion of Women in Oncology Clinical Trials From 2000 to 2020
In a study reported in a research letter in JAMA Oncology, Jenei et al found that women with cancer have been underrepresented in global oncology drug trials over the past 20 years, with underrepresentation persisting through the present in multiple cancer types. Study Details The study involved ...
Rates of Adverse Reactions to the Moderna mRNA-1273 COVID-19 Vaccine in Patients With Cancer and Recent Radiotherapy
In an Italian single-center study reported in a letter in The Lancet Oncology, Scoccianti et al found that patients who underwent radiotherapy for cancer within the 6 months prior to receipt of the Moderna mRNA-1273 COVID-19 vaccine did not experience a difference in adverse reactions to the...
Cancer-Specific Urgent Care Center: Effect on Emergency Department Use and Hospitalization Rate
In a single-institution study reported in JCO Oncology Practice, Gould Rothberg et al found that establishment of a dedicated cancer urgent care center within a large tertiary academic center resulted in a significant but modest decrease in emergency department use—but no significant reduction in...
Effect of Mindfulness Meditation and Survivorship Education on Depressive Symptoms in Younger Breast Cancer Survivors
In a phase III trial (Pathways to Wellness) reported in the Journal of Clinical Oncology, Julienne E. Bower, PhD, and colleagues found that both mindfulness meditation and survivorship education interventions significantly reduced depressive symptoms in younger breast cancer survivors. Study...
Novel Urine-Based Test Evaluated in Prostate Cancer Detection and Risk Stratification
In a validation study with data presented at the American Urological Association’s 2021 Annual Meeting, clinician-researchers reported that a new test (miR Sentinel PCC4 Test) may be able to detect and risk-classify prostate cancer at the molecular level with predictive accuracy based on a single...
Technology-Enabled Monitoring of Adverse Reactions to Immune Checkpoint Inhibitors
In an interim analysis of a single-institution study reported in JAMA Network Open, Pavlos Msaouel, MD, PhD, and colleagues found that the use of a mobile device application for patient reporting of adverse reactions to immune checkpoint inhibition was feasible. It permitted identification of...
Guideline Update Addresses Treatments for HER2-Negative Advanced Breast Cancer
In light of findings from multiple recent clinical trials in HER2-negative metastatic breast cancer, ASCO has revised its treatment recommendations to inform more evidence-based care for metastatic breast cancer.1 “This guideline update provides important clinical guidance about the new use of...
ELEVATE-RR Trial: Acalabrutinib as Effective as Ibrutinib, With Fewer Cardiac Effects, in Resistant CLL
Acalabrutinib was equally efficacious with less toxicity when compared directly with ibrutinib in patients with previously treated relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of an open-label, randomized, noninferiority phase III trial presented at the 2021...
Lutetium-177–PSMA-617: A First-in-Class Radioligand Therapeutic in Metastatic Prostate Cancer
Based on the findings of the phase III VISION trial, reported by Sartor et al1 and summarized in this issue of The ASCO Post, lutetium-177–PSMA-617 (LuPSMA) is the first of the prostate-specific membrane antigen–targeted cancer theranostics to demonstrate a survival-prolonging benefit for men with...
Recommendations From ASCO for Discussing Patients’ Goals of Care Through Survivorship to End of Life
In 2017, ASCO published its consensus guideline to provide guidance on how oncologists can use effective communication to maximize the patient-clinician relationship, patient and clinician well-being, and family well-being as well as form a trusting relationship with patients through empathy and...
Study Finds Lower Income Eligibility Limits for Medicaid Associated With Worse Long-Term Survival for Newly Diagnosed Patients With Cancer
A study investigating the association between state Medicaid income eligibility limits and long-term survival among newly diagnosed patients with cancer has found that patients living in states with lower Medicaid income eligibility limits had worse long-term survival compared with patients living ...
2021 Basser Global Prize Presented to André Nussenzweig, PhD
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania—the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers—has announced André Nussenzweig, PhD, of the National Cancer Institute (NCI), as the...
Effect of High-Intensity Interval Training on Biochemical Progression in Patients With Localized Prostate Cancer Under Active Surveillance
In a Canadian single-institution phase II study (ERASE) reported in JAMA Oncology, Kang et al found that increased exercise in the form of high-intensity interval training was associated with increased cardiorespiratory fitness and reductions in prostate-specific antigen (PSA) level, PSA velocity,...
Assumptions, Data … and More Questions!
I read with great interest the results from the phase II ZUMA-12 study of axicabtagene ciloleucel, presented during the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 But the results raised several questions for me. Axicabtagene ciloleucel, an autologous anti-CD19...
Pharmacy Strategy to Decrease Patient Copayments for High-Cost Cancer Drugs Through Financial Assistance Applications
In an observational retrospective study reported in JCO Oncology Practice, Seymour et al describe a strategy used by Karmanos Specialty Pharmacy (KSP) to successfully decrease patient copayments for high-cost cancer drugs. Study Details The study involved data from the KSP claims data set, accessed ...
HPV Vaccination and Projected Oropharyngeal Cancer Incidence Through the Year 2045
In a population-based age-period-cohort study reported in JAMA Oncology, Zhang et al estimated that current human papillomavirus (HPV) vaccination rates will have a limited impact on overall oropharyngeal cancer incidence through 2045, due to a high risk of oropharyngeal cancer in unvaccinated...
Rates of Newly Diagnosed Cancer Among U.S. Patients During the First Full Year of the COVID-19 Pandemic
In a study of Quest Diagnostics data reported as a research letter in JAMA Network Open, Kaufman et al found significant decreases in monthly new cancer diagnoses during the first full year of the COVID-19 pandemic compared with the prepandemic period. As stated by the investigators, “We previously ...
Teleoncology for Veterans With Cancer During the COVID-19 Pandemic
In a single-center study reported in JCO Oncology Practice, Jiang et al found an overall high level of satisfaction with teleoncology care during the COVID-19 pandemic among veterans with cancer in the United States, although a preference for in-person visits was commonly expressed. Teleoncology...
Phase II Trial Evaluates Oncolytic Coxsackievirus A21 for Unresectable Advanced Melanoma
In a phase II trial reported in the Journal of Clinical Oncology, Robert H.I. Andtbacka, MD, and colleagues found that intratumoral injection of the oncolytic RNA virus Coxsackievirus A21 (V937) was well tolerated and produced responses in some patients with unresectable stage III or stage IV...
Ibrutinib and Cardiovascular Risk in Patients With Chronic Lymphocytic Leukemia
In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Abdel-Qadir et al found that ibrutinib treatment for chronic lymphocytic leukemia (CLL) is associated with increased risks of atrial fibrillation, bleeding, and heart failure, but not ischemic stroke or acute...
Effect of Concurrent Focal 22q11.22 Deletions and IKZF1 Alterations on Outcomes in Pediatric Patients With B-Cell ALL
In a study reported in JAMA Oncology, Mangum et al found that focal deletions in chromosome 22q11.22 were associated with poor outcomes in pediatric patients with B-cell acute lymphoblastic leukemia (ALL) with IKZF1 alterations. As stated by the investigators, “Alterations in the IKZF1 gene drive...
Early-Stage Research on Dual-Action Estrogen Receptor Inhibitors for Breast Cancer
A set of compounds developed by scientists at Scripps Research target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers. More information on these dual-mechanism estrogen receptor inhibitors was published by Min et...
Effects of COVID-19 Infection in Children and Adolescents With Cancer: Global Analysis
In a Global Registry of COVID-19 in Childhood Cancer cohort study reported in The Lancet Oncology, Mukkada et al found that approximately one-fifth of children with cancer infected with COVID-19 worldwide had severe illness, with an associated mortality rate exceeding that reported in the general...
Addition of Venetoclax to Daratumumab/Dexamethasone With or Without Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
In a phase I study reported in the Journal of Clinical Oncology, Bahlis et al found that venetoclax plus daratumumab/dexamethasone (VenDd) and VenDd with bortezomib (VenDVd) produced high rates of durable responses in patients with relapsed or refractory multiple myeloma with t(11;14) translocation ...
Inguinofemoral Radiotherapy vs Inguinofemoral Lymphadenectomy for Patients With Vulvar Cancer and Sentinel Node Metastasis
In the phase II GROINSS-V II study reported in the Journal of Clinical Oncology, Oonk et al found that inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy in women with early-stage vulvar cancer and sentinel node micrometastasis but was associated with a higher...
Global Breast Cancer Survival: Estimated Impact of Scaling Up Access to Treatment/Imaging Modalities and Quality of Care
In a study reported in The Lancet Oncology, Ward et al estimated the improvements in global overall survival for female breast cancer that could be achieved via increased availability of treatment and imaging modalities, as well as improvements in quality of care. Study Details The study used a...
Pharmacologic Cardioprotection in Women With Nonmetastatic Breast Cancer Receiving Anthracycline-Based Chemotherapy
In an interim analysis of the Italian phase III SAFE trial reported in JAMA Oncology, Livi et al found that a cardioprotective strategy using ramipril and/or bisoprolol reduced the risk of myocardial dysfunction in women with nonmetastatic breast cancer receiving anthracycline-based chemotherapy....
ALK Fusion–Positive High-Grade Glioma: Response to Lorlatinib in a Single Pediatric Case
In a letter to the editor published in The New England Journal of Medicine, Bagchi et al describe the course of treatment in a 3-year-old child with an intracranial tumor and his response to therapy with the kinase inhibitor lorlatinib. Key Points Magnetic resonance imaging (MRI) of the head in a...
Effects of Removing Race in the CKD-EPI Equation for Estimated Glomerular Filtration Rate
In a study reported in The Lancet Oncology, Casal et al showed that removing race as a factor in the Chronic Kidney Disease–Epidemiology Collaboration (CKD-EPI) equation for estimated glomerular filtration rate (eGFR) would result in calculation of a lower eGFR in Black patients. This might result...
Personalized Risk Prediction Model for Patients With Myelodysplastic Syndromes
As reported in the Journal of Clinical Oncology, Aziz Nazha, MD, and colleagues have developed a model for predicting the risk of disease progression for individual patients with myelodysplastic syndromes (MDS). To develop the prediction model for overall survival and leukemic transformation,...
Two Studies Explore the Role of Primary Care Providers in Effective Cancer Care
Communication between patients and their primary care providers is key to ensuring effective cancer care, both before diagnosis and after treatment, according to two recent papers authored by University of Michigan Rogel Cancer Center researchers. Although each study analyzed different stages of...
Prostate Cancer Screening Using the Stockholm3 Screening Test With MRI-Guided Biopsy
In a Swedish prostate cancer screening trial (STHLM3-MRI) reported in The Lancet Oncology, Nordström et al found that use of the Stockholm3 screening test together with magnetic resonance imaging (MRI)-guided biopsy reduced overdetection of disease while preserving the ability to detect clinically...
Cancer Predisposition Screening Tool for Predicting Subsequent Malignancies in Childhood Cancer Survivors
In a Canadian study reported in the Journal of Clinical Oncology, Cullinan et al found that the McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) tool provided predictive value for risk of subsequent malignant neoplasms in childhood cancer survivors beyond risk associated with treatment...
Profile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based Therapy
In a systematic review and meta-analysis reported in The Lancet Oncology, Zhou et al provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Study Details The...
Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...
Historic, Present, and Future Perspectives on Breast Cancer in Egypt
Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...
Axicabtagene Ciloleucel Improves Multiple Clinical Endpoints in Relapsed Follicular Lymphoma
For the treatment of relapsed or refractory follicular lymphoma, updated data from the ZUMA-5 trial, as compared with the findings of the external control cohort of SCHOLAR-5, showed substantial improvement in all key clinical endpoints with axicabtagene ciloleucel, ZUMA-5 investigators reported in ...
Adjuvant Pembrolizumab May Improve Disease-Free Survival in Patients With High-Risk Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, an interim analysis of the phase III KEYNOTE-564 trial showed improved disease-free survival with adjuvant pembrolizumab vs placebo after nephrectomy in high-risk patients with clear cell renal cell...
Non–Testicular Cancer Mortality Rates in Men With Testicular Cancer in the Cisplatin Era
In a Norwegian population-based study reported in the Journal of Clinical Oncology, Hellesnes et al found that treatment of testicular cancer with platinum-based chemotherapy or radiotherapy was associated with a significant excess of non–testicular cancer mortality compared with the general...
NTRK Fusion–Positive Non–Small Cell Lung Cancer
In this video, Drs. Justin F. Gainor, Ibiayi Dagogo-Jack, and Jyoti D. Patel discuss the management of NTRK fusion–positive non–small cell lung cancer (NSCLC). Dr. Gainor presents the case of a 44-year-old man with a 5 pack-year history of tobacco exposure who was diagnosed with metastatic NSCLC;...
Excess Cardiovascular Disease Risk in Patients With Early-Stage Lymphoma: Personalizing Radiotherapy Delivery
As reported in the Journal of Clinical Oncology by Cutter et al, an analysis from the UK NCRI RAPID trial of positron-emission tomography (PET)-directed therapy in patients with early-stage Hodgkin lymphoma indicated that the use of involved-field radiotherapy in PET-negative patients who had...
Combination of Lenvatinib and Etoposide/Ifosfamide for Relapsed or Refractory Osteosarcoma
In the phase I/II ITCC-050 trial reported in The Lancet Oncology, Gaspar et al found that the combination of lenvatinib with etoposide/ifosfamide showed antitumor activity, including good progression-free survival outcomes, in patients with relapsed or refractory osteosarcoma. Study Details...
